Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma

NCT03441958 is registered in ClinicalTrials.gov with Ciusss de L'Est de l'Île de Montréal as lead sponsor.

NCT NCT03441958
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03441958 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Open-label Study of Reduced Intensity-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma
Lead sponsor
Ciusss de L'Est de l'Île de Montréal
Phase
Phase 1/2
Overall status
Completed
Start date
March 7, 2018
Completion date
October 17, 2025
Enrollment
19 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma